Convalescent Plasma Therapy trials for COVID-19 to begin in Delhi

Countries such as China, South Korea, US and UK have been trying CPT

Convalescent Plasma Therapy, Arvind Kejriwal, Delhi, COVID-19, ICU

Delhi is slated to carry out clinical trials of convalescent plasma therapy (CPT) to help critically ill coronavirus patients, after getting centre’s approval. CPT is meant only for critical COVID-19 patients, said Chief Minister Arvind Kejriwal.

“The only way to permanently tackle coronavirus is for the vaccine to be available. However, if people are infected, they want a safe recovery from the disease. If the patient has some other ailment, the risk is higher. In such cases, if plasma technology is used the results are good," Kejriwal said at a press conference. “We hope that this trial is successful and this will give some hope. Kerala and Maharashtra are also working on this," Kejriwal added.

CPT involves transfusion of plasma from a convalescent coronavirus patient to a critical patient.  In plasma therapy, about 800 ml of blood is extracted from a recovered coronavirus patient to isolate plasma rich with antibodies. This plasma is then infused into the blood stream of other coronavirus patients. When the body gets into contact with external pathogens like bacteria or germs, it automatically triggers a defence mechanism, releasing antibodies.

Countries such as China, South Korea, US and UK have been trying  CPT.